CTO Realty Growth reported a Q3 2026 Core FFO of $0.53 per diluted share, up 10% year-over-year, despite a net loss of $0.19 per share. The company invested $472 million year-to-date at a 9.4% average yield and secured a $1 billion credit facility extending debt maturity to 2029. Same-property NOI grew 3.8% in Q3, and leasing momentum remains strong with a $5.6 million signed-not-open pipeline. CTO raised its 2026 Core FFO guidance to $2.11-$2.14 per share, signaling confidence in continued earnings growth into 2027.
CTO Realty Growth's Q3 2026 results provide context for readers interested in real estate. For readers following the Real Estate sector, here is Pluang's market snapshot as of Oct 28, 2026 02:51 WIB: Of 47 priced US Real Estate stocks tradable on Pluang, 17 rose and 30 fell today. Notable movers include VTR at USD 83.28 with a -4.74% change, AHR at USD 51.06 down 4.65%, and ARE at USD 41.46 with 100% sell order activity and a -4.47% change. The most notable figure is ARE's 95-day typical hold time on Pluang.
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
argenx SE announced it will stop its Phase 3 UNITY study of efgartigimod subcutaneous for moderate-to-severe Sjögren's disease after an independent committee found the trial unlikely to meet its primary goal. This decision caused the company's stock ...
Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop triggered by a new U.S. federal strategy targeting the dialysis market. The Department of Health and Human Services announced a plan to incre...
Pomerantz LLP is investigating ClearPoint Neuro and its executives for possible securities fraud following a significant stock price drop. The decline occurred after ClearPoint's partner, uniQure, announced that their Huntington's disease treatment f...
